Tumor Biology, a Springer journal, retracted 107 articles in a single notice Thursday.

　　斯普林格出版社旗下的期刊《肿瘤生物学》在周四的一则通知中宣布撤回107篇论文。

　　The supposedly peer-reviewed papers did not appropriately go through the peer-review process, the publisher and editor of the paper writes in a terse note accompanying the list of discredited studies.

　　论文出版社、编辑用简洁的口吻写道，本应经过同行评审的论文没有正规地完成这一流程，随附还有疑似论文的名单。

　　“After a thorough investigation we have strong reason to believe that the peer review process was compromised,” they write.

　　他们写道：“在全面调查后，我们有足够的理由相信同行评审是编造的。”

　　The papers are predominantly authored by scientists from China, and were published from 2012 up until last year.

　　这些论文的作者主要是来自中国的科学家，发表时间为2012年至去年。

　　The subjects span from the impacts of smoking on cancer, to gene-specific effects on tumors. The variety of cancers spans the gamut, from the gastric system to bones, the prostate, lung, liver and other tumors.

　　论文主题涵盖抽烟对于癌症的影响、基因独特性对于肿瘤的影响。癌症类别包括消化系统癌、骨骼癌、前列腺癌、肺癌、肝癌和其它肿瘤。

　　The site Sixth Tone first reported on the massive retraction. One of Springer’s editorial directors told the Chinese media outlet that the studies had been submitted with suggestions from reviewers with real names – but with fabricated email addresses. Follow-up determined that the real scientists were never contacted to review their peers’ work, according to the report.

　　《第六声》网站首先报道了此次大规模撤回事件。斯普林格出版社的一名编辑主任向中国的媒体表示，这些论文提交时附有实名评审员的意见，但是邮箱是捏造的。据报道，后文断定真正的科学家从未被联系来评论他们同行的作品。

　　Springer is not the first major publisher to discover widespread peer review problems prompting mass retractions. BioMed Central retracted 43 papers in one action in November 2014, and Hindawi Publishing Corporation announced in 2015 that three editors had “subverted” the entire editorial process in publishing 32 papers.

　　斯普林格并非是首家发现大量同行评审问题、发起大规模撤回的重要出版社。2014年11月，BioMed Central曾一次性撤回过43篇论文，Hindawi出版社于2015年宣布，三名编辑“破坏了”32篇论文发布的整个编辑过程。

（编辑：何莹莹）